undamentalytics Newsletter
Sign in

Maia Biotechnology, Inc. (MAIA) stock

Add to watchlist

Add holding +

NYSE: MAIA NYSE Biotechnology

Maia Biotechnology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders7 buying, 0 selling29 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds22 adding, 12 cuttingOf 7 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 18% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Maia Biotechnology, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 86% and a beta of 1.6 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$0.13 against an average estimate of -$0.11: missed by 18.2%
Share reaction
-3.7% in the first session after the results on November 7, 2023, against +0.4% for the S&P 500

Maia Biotechnology's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-0.9%
  • 1 month-7.6%
  • This year-28.1%
  • 1 year-11.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
November 7, 2023

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Maia Biotechnology, Inc. valuation models and calculator

No model value for Maia Biotechnology, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Maia Biotechnology, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.2 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Maia Biotechnology, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.54 +27% — 0%
Next $1.11 +306% — 0%

Next year's EPS estimate has moved −0.9% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +3.8% on 90 days ago. In the last 30 days, 0 analysts raised Maia Biotechnology, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Maia Biotechnology, Inc., last 90 days
−$1.00 −$0.50 $0.00 $0.50 $1.00 $1.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.52 Current fiscal year, 60 days ago: −$0.52 Current fiscal year, 30 days ago: −$0.52 Current fiscal year, 7 days ago: −$0.52 Current fiscal year, Now: −$0.54 −$0.54 Next fiscal year, 90 days ago: $1.12 Next fiscal year, 60 days ago: $1.12 Next fiscal year, 30 days ago: $1.11 Next fiscal year, 7 days ago: $1.11 Next fiscal year, Now: $1.11 $1.11

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.52$1.12
60 days ago −$0.52$1.12
30 days ago −$0.52$1.11
7 days ago −$0.52$1.11
Now −$0.54$1.11

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.11 −$0.13 −18.2%
Mar 2026 −$0.18 −$0.14 +22.2%
Dec 2025 −$0.13 −$0.14 −5.2%
Sept 2025 −$0.19 −$0.27 −42.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611
  3. Aug 202611
  4. Jul 202611

Counts of recommendations published by analysts covering Maia Biotechnology, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.4%
of tradable shares
Days to cover
3.97
at average volume
Short interest, 1 month
+20%
to October 15, 2026
Held by institutions
22%
of shares
Held by insiders
14.4%
of shares
Employees
13
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
MAIA−67%+69%−23%−28%
Industry peers (median)−17%−29%−5%−26%
S&P 500+26%+25%+18%+11%
Months that ended higher
MAIA42%33%25%36%
S&P 50067%75%75%46%
Largest fall from a high during the year
MAIA−83%−62%−65%−64%
S&P 500−10%−8%−19%−9%

Worst fall since July 28, 2022: 89% from August 1, 2022 to December 12, 2023. Getting back needed a 840% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.87 – $2.95
From 52-week high
−62.7%
vs 50-day average
−11.2%
vs 200-day average
−24.5%
Volatility (1 year)
86%
Beta vs S&P 500
1.63

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 3 down
typical move ±5.4%
After a week
2 up, 4 down
typical move ±7.6%
After a month
0 up, 6 down
typical move ±21.9%
Results releasedNext dayS&P 500 next day5 days21 days
November 7, 2023 −3.7% +0.4% −13.9% −57.8%
August 8, 2023 +1.4% −1.1% −3.8% −16.2%
May 8, 2023 −5.3% −0.4% −4.9% −17.1%
March 24, 2023 +12.1% +0.8% +12.7% −25.1%
November 9, 2022 −5.6% +3.3% +4.2% −2.8%
August 22, 2022 +4.1% −2.3% −6.1% −12.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$19.4M
Institutions reporting
36
Shares held vs prior quarter
▲ 2.8%
Positions opened / closed
13 / 9

Top buyers and sellers, Q2 2026: 22 institutions bought and 12 sold ; the biggest buyer was Renaissance Technologies LLC (+416K shares) and the biggest seller Solas Capital Management, LLC (−1.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Solas Capital Management, LLC $4.4M 3.0M 22.5% ▼ 29.5%
Alyeska Investment Group, L.P. $3.6M 2.5M 18.5% 0.0%
Vanguard Capital Management LLC $3.5M 2.4M 17.9% ▲ 16.4%
683 Capital Management, LLC $1.5M 1.1M 7.9% 0.0%
Centric Wealth Management $1.1M 797K 5.7% 0.0%
Cable Car Capital, LP $741,000 515K 3.8% ▼ 20.7%
Geode Capital Management, LLC $726,568 504K 3.7% ▲ 39.9%
Bleichroeder LP $720,000 500K 3.7% 0.0%
Renaissance Technologies LLC $598,608 416K 3.1% New
Blackrock, Inc. $580,335 403K 3.0% ▲ 214.9%
Vanguard Fiduciary Trust Co $484,831 337K 2.5% ▲ 68.9%
State Street Corp $290,520 202K 1.5% ▲ 45.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Maia Biotechnology, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.1M 29 trades by 7 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.1M net buying
Insider Date Trade Shares Price Value
Vitoc Vlad Chief Executive Officer September 14, 2026 Buy 73,000 $1.37 $100,010
Guerrero Ramiro Director September 10, 2026 Buy 37,595 $1.32 $49,625
Guerrero Ramiro Director August 28, 2026 Buy 46,620 $1.35 $62,937
Guerrero Ramiro Director August 27, 2026 Buy 78,239 $1.39 $108,752
Guerrero Ramiro Director August 26, 2026 Buy 8,931 $1.39 $12,414
Guerrero Ramiro Director August 24, 2026 Buy 1,794 $1.33 $2,386
Guerrero Ramiro Director August 20, 2026 Buy 11,899 $1.37 $16,302
Gryaznov Sergei Chief Scientific Officer June 1, 2026 Buy 2,000 $1.35 $2,700
Smith Stan Director June 1, 2026 Buy 75,000 $1.34 $100,500
Vitoc Vlad Chief Executive Officer June 1, 2026 Buy 72,700 $1.39 $101,053
Louie Ngar Yee Director December 22, 2025 Buy 81,699 $1.22 $99,673
Chaouki Steven M Director December 22, 2025 Buy 40,849 $1.22 $49,836

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around February 6, 2024 estimated from the company's past filing pattern, not announced

  • November 7, 2023
  • August 8, 2023
  • May 8, 2023
  • March 24, 2023
  • November 9, 2022
  • August 22, 2022

Recent SEC filings

Data status

When each part of this page on Maia Biotechnology, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Maia Biotechnology, Inc. in brief

What does Maia Biotechnology, Inc. do?
Maia Biotechnology, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Maia Biotechnology, Inc.'s stock ticker?
Maia Biotechnology, Inc. trades under the ticker MAIA on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Maia Biotechnology, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Solas Capital Management, LLC, Alyeska Investment Group, L.P. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Maia Biotechnology, Inc. stock?
Over the last 12 months, Maia Biotechnology, Inc.'s directors and officers reported 29 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.